Efficacy and safety of lorecivivint for the treatment of knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 42402776 · doi:10.1177/10225536261466342
What was done
The authors conducted a systematic review and meta-analysis of randomized controlled trials published up to January 2026 evaluating intra-articular lorecivivint (a Wnt pathway inhibitor) compared with placebo in patients with knee osteoarthritis. The review pooled data from 6 RCTs encompassing 2,179 patients to assess pain, physical function, patient global assessment, structural changes, and safety outcomes across different doses (including 0.07 mg).
What was found
Lorecivivint achieved modest reductions in WOMAC pain scores at weeks 12 and 24 compared to placebo. It showed no statistically significant benefits in Pain Numeric Rating Scale scores, functional outcomes, patient global assessment, or structural disease progression. Subgroup analyses revealed no consistent dose-response relationship, with no meaningful improvement observed at the 0.07 mg dose. Safety profiles were comparable to placebo. Specific effect sizes, point estimates, and confidence intervals were not reported in the abstract.
Why it matters
Lorecivivint has been investigated as a potential disease-modifying osteoarthritis drug, but this pooled evidence demonstrates that its clinical impact is limited to modest pain score improvements without structural preservation or functional gain.
Limits
The abstract does not report specific numerical values, point estimates, confidence intervals, or heterogeneity metrics. The evidence base comprises only 6 trials with assessment limited to intermediate time points (up to 24 weeks), leaving long-term disease modification unclear.
Cited by
- contradicts Biosplice's osteoarthritis treatment is a single injection that regrows all tendons in 11 months to the state of 16-year-old tendons.